Korean companies eyes capecitabine market

Published: 2010-03-30 06:58:00

Updated: 2010-03-30 06:58:00

As the re-examination of capecitabine is to be expired on July 30, several drug makers, such as Ildong, Boryung, Daewoong, Dong-A and Samyang Corporation, are setting their sights on the domestic capecitabine market valued at 10.9 billion won last year.

Capecitabine is an oral drug marketed by...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK